CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results
STAAR Surgical reported strong Q3 2024 financial results with net sales up 10% to $88.6 million, driven by growth across all regions: Americas (+14%), EMEA (+12%), and APAC (+9%). The company achieved ICL sales of $89.1 million, also up 10% year-over-year, with unit growth of 6%. Net income reached $10.0 million ($0.20 per share), increasing from $4.8 million ($0.10 per share) in the previous year.
Despite a softening macroeconomic environment, particularly in China during the second half of the quarter, STAAR maintained its fiscal year 2024 outlook with projected net sales of $340-345 million and Adjusted EBITDA of approximately $42 million. The company ended the quarter with $236.0 million in cash, cash equivalents, and investments.
STAAR Surgical ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con vendite nette in aumento del 10% a $88,6 milioni, trainate dalla crescita in tutte le regioni: Americhe (+14%), EMEA (+12%) e APAC (+9%). L'azienda ha raggiunto vendite di ICL per $89,1 milioni, anch'esse in aumento del 10% rispetto all'anno precedente, con una crescita delle unità del 6%. Il reddito netto ha raggiunto $10,0 milioni ($0,20 per azione), in aumento rispetto ai $4,8 milioni ($0,10 per azione) dell'anno precedente.
Nonostante un ambiente macroeconomico in rallentamento, particolarmente in Cina nella seconda metà del trimestre, STAAR ha mantenuto le previsioni per l'anno fiscale 2024 con vendite nette previste tra $340-345 milioni e un EBITDA rettificato di circa $42 milioni. L'azienda ha chiuso il trimestre con $236,0 milioni in cassa, equivalenti di cassa e investimenti.
STAAR Surgical informó resultados financieros sólidos para el tercer trimestre de 2024, con ventas netas que aumentaron un 10% a $88.6 millones, impulsadas por el crecimiento en todas las regiones: Américas (+14%), EMEA (+12%) y APAC (+9%). La compañía logró ventas de ICL de $89.1 millones, también un 10% más que el año anterior, con un crecimiento de unidades del 6%. El ingreso neto alcanzó $10.0 millones ($0.20 por acción), aumentando desde $4.8 millones ($0.10 por acción) en el año anterior.
A pesar de un ambiente macroeconómico debilitado, particularmente en China durante la segunda mitad del trimestre, STAAR mantuvo su perspectiva para el año fiscal 2024 con ventas netas proyectadas de $340-345 millones y un EBITDA ajustado de aproximadamente $42 millones. La compañía finalizó el trimestre con $236.0 millones en efectivo, equivalentes de efectivo e inversiones.
STAAR Surgical는 2024년 3분기 재무 결과가 매우 강력하다고 보고했습니다. 순매출이 10% 증가하여 8,860만 달러에 달했으며, 이는 모든 지역에서의 성장이 주효했습니다: 아메리카 (+14%), EMEA (+12%) 및 APAC (+9%). 회사는 ICL 매출이 8,910만 달러에 달했고, 이는 경년 대비 10% 증가했으며, 유닛 성장률은 6%였습니다. 순이익은 1천만 달러 ($0.20 주당주)로, 지난해의 480만 달러 ($0.10 주당주)에서 증가했습니다.
특히 분기 후반기에 중국에서의 경기 침체에도 불구하고, STAAR는 2024 회계연도 전망을 유지했으며 순매출은 3억4천만~3억4천5백만 달러, 조정된 EBITDA는 약 4천2백만 달러로 예상하고 있습니다. 회사는 2억3천6백만 달러의 현금, 현금성 자산 및 투자를 보유하고 분기를 마감했습니다.
STAAR Surgical a annoncé de solides résultats financiers pour le troisième trimestre 2024, avec des ventes nettes en augmentation de 10 % à 88,6 millions de dollars, soutenues par la croissance dans toutes les régions : Amériques (+14 %), EMEA (+12 %) et APAC (+9 %). L'entreprise a atteint des ventes d'ICL de 89,1 millions de dollars, également en hausse de 10 % par rapport à l'année précédente, avec une croissance des unités de 6 %. Le revenu net a atteint 10,0 millions de dollars (0,20 $ par action), en hausse par rapport aux 4,8 millions de dollars (0,10 $ par action) de l'année précédente.
Malgré un environnement macroéconomique affaibli, en particulier en Chine durant la seconde moitié du trimestre, STAAR a maintenu ses prévisions pour l'exercice 2024, avec des ventes nettes projetées entre 340 et 345 millions de dollars et un EBITDA ajusté d'environ 42 millions de dollars. L'entreprise a terminé le trimestre avec 236,0 millions de dollars en espèces, équivalents de trésorerie et investissements.
STAAR Surgical berichtete über starke finanzielle Ergebnisse im 3. Quartal 2024, mit Nettoumsätzen, die um 10 % auf 88,6 Millionen USD gestiegen sind, was durch Wachstum in allen Regionen angetrieben wurde: Amerika (+14 %), EMEA (+12 %) und APAC (+9 %). Das Unternehmen erzielte ICL-Verkäufe von 89,1 Millionen USD, ebenfalls um 10 % im Jahresvergleich gestiegen, mit einem Wachstum der Einheiten um 6 %. Der Nettogewinn belief sich auf 10,0 Millionen USD (0,20 USD pro Aktie), ein Anstieg von 4,8 Millionen USD (0,10 USD pro Aktie) im Vorjahr.
Trotz eines sich abschwächenden makroökonomischen Umfelds, insbesondere in China in der zweiten Hälfte des Quartals, hielt STAAR an seinen Prognosen für das Geschäftsjahr 2024 fest, mit prognostizierten Nettoumsätzen von 340 bis 345 Millionen USD und einem bereinigten EBITDA von etwa 42 Millionen USD. Das Unternehmen beendete das Quartal mit 236,0 Millionen USD an Bargeld, Zahlungsmitteläquivalenten und Investitionen.
- None.
- None.
Net Sales Up
Americas Up
Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity
The updated release reads:
STAAR SURGICAL REPORTS THIRD QUARTER 2024 RESULTS
Net Sales Up
Americas Up
Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024.
Third Quarter 2024 Overview
-
Net sales of
, up$88.6 million 10% from prior year quarter -
ICL sales of
, up$89.1 million 10% from prior year quarter -
Gross margin of
77.3% as compared to79.2% year ago -
Net income of
or$10.0 million per share, up from$0.20 or$4.8 million per share year ago$0.10 -
Adjusted EBITDA of
or$16.2 million per share as compared to$0.33 or$16.5 million per share year ago$0.33 -
of cash, cash equivalents and investments available for sale as of September 27, 2024$236.0 million
“In the third quarter, we achieved double-digit sales growth against a macroeconomic environment that softened in the second half of the quarter, particularly in China,” said Tom Frinzi, President and CEO of STAAR Surgical. “STAAR is well positioned to navigate through the current market dynamics, which we believe are transitory. Looking ahead, we are encouraged by the recent shift in fiscal policy and announced stimulus in
Mr. Frinzi concluded, “Our focus on customer engagement and market expansion continues to yield solid results, helping drive industry-leading growth and market share gains. As our surgeon customers perform more EVO procedures, they are increasingly using our technology for moderate myopia, which underscores EVO ICL as the treatment choice for -6D and above and expands our total addressable market.”
Third Quarter 2024 Financial Results
Net sales were
Gross profit margin for the third quarter of 2024 was
Operating expenses for the third quarter of 2024 were
Operating income for the third quarter of 2024 was
Net income for the third quarter of 2024 was
As of September 27, 2024, cash, cash equivalents and investments available for sale totaled
Outlook
The Company maintained its prior outlook for fiscal year 2024 net sales and Adjusted EBITDA.
-
Net sales of
to$340 million .$345 million -
Adjusted EBITDA of approximately
and Adjusted EBITDA per diluted share of approximately$42 million .$0.80
The outlook above contemplates EVO ICL sales growth of
Earnings Webcast
The Company will host an earnings webcast today, Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the webcast please use the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB.
The live webcast, earnings webcast presentation and an archived version of the webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
Use of Non-GAAP Financial Measures
To supplement the Company’s financial measures prepared in accordance with
EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net income. In calculating Adjusted EBITDA and Adjusted EBITDA per diluted share, the Company further adjusts for stock-based compensation expense. As stock-based compensation is a non-cash expense that can vary significantly based on the timing, size and nature of awards granted, the Company believes that the exclusion of stock-based compensation expense can assist investors in comparisons of Company operating results with other peer companies because (i) the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expense can vary significantly between periods as a result of the timing of grants of new stock-based awards, including inducement grants in connection with hiring. Additionally, the Company believes that excluding stock-based compensation from Adjusted EBITDA and Adjusted EBITDA per diluted share assists management and investors in making meaningful comparisons between the Company’s operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.
The Company also presents certain financial information on a constant currency basis, which is intended to exclude the effects of foreign currency fluctuations. The Company conducts a significant part of its activities outside the
In the tables provided below, the Company has included a reconciliation of Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share, the most directly comparable GAAP financial measure, as well as supplemental financial information with net sales expressed in constant currency. The Company has also provided a reconciliation of forward-looking Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share. This represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Safe Harbor section of this press release.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted share), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the upcoming quarter, fiscal year 2024 and beyond. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 29, 2023 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of COVID-19; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international conflicts, trade disputes and substantial dependence on demand from
We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
Consolidated Balance Sheets | ||||||||
(in 000's) | ||||||||
Unaudited | ||||||||
ASSETS | September 27, 2024 | December 29, 2023 | ||||||
Current assets: | ||||||||
Cash and cash equivalents | $ |
164,003 |
|
$ |
183,038 |
|
||
Investments available for sale |
|
71,955 |
|
|
37,688 |
|
||
Accounts receivable trade, net |
|
104,510 |
|
|
94,704 |
|
||
Inventories, net |
|
40,361 |
|
|
35,130 |
|
||
Prepayments, deposits, and other current assets |
|
16,277 |
|
|
14,709 |
|
||
Total current assets |
|
397,106 |
|
|
365,269 |
|
||
Investments available for sale |
|
- |
|
|
11,703 |
|
||
Property, plant, and equipment, net |
|
81,580 |
|
|
66,835 |
|
||
Finance lease right-of-use assets, net |
|
73 |
|
|
183 |
|
||
Operating lease right-of-use assets, net |
|
37,897 |
|
|
34,387 |
|
||
Goodwill |
|
1,786 |
|
|
1,786 |
|
||
Deferred income taxes |
|
5,324 |
|
|
5,190 |
|
||
Other assets |
|
13,824 |
|
|
3,339 |
|
||
Total assets | $ |
537,590 |
|
$ |
488,692 |
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ |
14,694 |
|
$ |
13,557 |
|
||
Obligations under finance leases |
|
84 |
|
|
165 |
|
||
Obligations under operating leases |
|
4,531 |
|
|
4,202 |
|
||
Allowance for sales returns |
|
8,124 |
|
|
6,174 |
|
||
Other current liabilities |
|
38,908 |
|
|
40,938 |
|
||
Total current liabilities |
|
66,341 |
|
|
65,036 |
|
||
Obligations under finance leases |
|
- |
|
|
42 |
|
||
Obligations under operating leases |
|
35,385 |
|
|
31,425 |
|
||
Deferred income taxes |
|
1,056 |
|
|
1,077 |
|
||
Asset retirement obligations |
|
127 |
|
|
103 |
|
||
Pension liability |
|
6,559 |
|
|
5,055 |
|
||
Total liabilities |
|
109,468 |
|
|
102,738 |
|
||
Stockholders' equity: | ||||||||
Common stock |
|
493 |
|
|
488 |
|
||
Additional paid-in capital |
|
466,579 |
|
|
436,947 |
|
||
Accumulated other comprehensive loss |
|
(5,602 |
) |
|
(4,113 |
) |
||
Accumulated deficit |
|
(33,348 |
) |
|
(47,368 |
) |
||
Total stockholders' equity |
|
428,122 |
|
|
385,954 |
|
||
Total liabilities and stockholders' equity | $ |
537,590 |
|
$ |
488,692 |
|
Consolidated Statements of Income | ||||||||||||||||||||||||||||||||||||
(in 000's except for per share data) | ||||||||||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||
Three Months Ended | Year to Date | |||||||||||||||||||||||||||||||||||
% of Sales |
|
September 27, 2024 |
|
% of Sales |
|
September 29, 2023 |
|
Fav (Unfav) Amount |
|
% |
|
% of Sales |
|
September 27, 2024 |
|
% of Sales |
|
September 29, 2023 |
|
Fav (Unfav) Amount |
|
% |
||||||||||||||
Net sales |
|
$ |
88,590 |
|
$ |
80,308 |
|
$ |
8,282 |
|
|
|
$ |
264,951 |
|
$ |
246,142 |
|
$ |
18,809 |
|
|
||||||||||||||
Cost of sales |
|
|
20,103 |
|
|
|
16,670 |
|
|
(3,433 |
) |
(20.6)% |
|
|
57,017 |
|
|
|
54,216 |
|
|
(2,801 |
) |
(5.2)% |
||||||||||||
Gross profit |
|
|
68,487 |
|
|
|
63,638 |
|
|
4,849 |
|
|
|
|
207,934 |
|
|
|
191,926 |
|
|
16,008 |
|
|
||||||||||||
Selling, general and administrative expenses: | ||||||||||||||||||||||||||||||||||||
General and administrative |
|
|
21,685 |
|
|
|
19,266 |
|
|
(2,419 |
) |
(12.6)% |
|
|
68,554 |
|
|
|
55,461 |
|
|
(13,093 |
) |
(23.6)% |
||||||||||||
Selling and marketing |
|
|
26,623 |
|
|
|
26,607 |
|
|
(16 |
) |
(0.1)% |
|
|
82,150 |
|
|
|
85,238 |
|
|
3,088 |
|
|
||||||||||||
Research and development |
|
|
14,497 |
|
|
|
11,470 |
|
|
(3,027 |
) |
(26.4)% |
|
|
41,931 |
|
|
|
33,535 |
|
|
(8,396 |
) |
(25.0)% |
||||||||||||
Total selling, general, and administrative expenses |
|
|
62,805 |
|
|
|
57,343 |
|
|
(5,462 |
) |
(9.5)% |
|
|
192,635 |
|
|
|
174,234 |
|
|
(18,401 |
) |
(10.6)% |
||||||||||||
Operating income |
|
|
5,682 |
|
|
|
6,295 |
|
|
(613 |
) |
(9.7)% |
|
|
15,299 |
|
|
|
17,692 |
|
|
(2,393 |
) |
(13.5)% |
||||||||||||
Other income (expense): | ||||||||||||||||||||||||||||||||||||
Interest income, net |
|
|
1,407 |
|
|
|
1,690 |
|
|
(283 |
) |
(16.7)% |
|
|
4,358 |
|
|
|
5,287 |
|
|
(929 |
) |
(17.6)% |
||||||||||||
Gain (loss) on foreign currency transactions |
|
|
5,931 |
|
- |
|
(1,384 |
) |
|
7,315 |
|
|
|
|
585 |
|
- |
|
(3,240 |
) |
|
3,825 |
|
|
||||||||||||
Royalty income |
|
|
- |
|
|
|
74 |
|
|
(74 |
) |
(100.0)% |
|
|
508 |
|
|
|
74 |
|
|
434 |
|
|
||||||||||||
Other income, net |
|
|
139 |
|
|
|
71 |
|
|
68 |
|
|
|
|
532 |
|
|
|
144 |
|
|
388 |
|
|
||||||||||||
Total other income, net |
|
|
7,477 |
|
|
|
451 |
|
|
7,026 |
|
|
|
|
5,983 |
|
|
|
2,265 |
|
|
3,718 |
|
|
||||||||||||
Income before provision for income taxes |
|
|
13,159 |
|
|
|
6,746 |
|
|
6,413 |
|
|
|
|
21,282 |
|
|
|
19,957 |
|
|
1,325 |
|
|
||||||||||||
Provision for income taxes |
|
|
3,179 |
|
|
|
1,929 |
|
|
(1,250 |
) |
(64.8)% |
|
|
7,262 |
|
|
|
6,366 |
|
|
(896 |
) |
(14.1)% |
||||||||||||
Net income |
|
|
9,980 |
|
|
|
4,817 |
|
|
5,163 |
|
|
|
|
14,020 |
|
|
|
13,591 |
|
|
429 |
|
|
||||||||||||
Net income per share - basic |
|
0.20 |
|
|
0.10 |
|
|
0.29 |
|
|
0.28 |
|
||||||||||||||||||||||||
Net income per share - diluted |
|
0.20 |
|
|
0.10 |
|
|
0.28 |
|
|
0.27 |
|
||||||||||||||||||||||||
Weighted average shares outstanding - basic |
|
49,199 |
|
|
48,613 |
|
|
49,078 |
|
|
48,426 |
|
||||||||||||||||||||||||
Weighted average shares outstanding - diluted |
|
49,731 |
|
|
49,370 |
|
|
49,614 |
|
|
49,494 |
|
Consolidated Statements of Cash Flows | ||||||||||||||||
(in 000's) | ||||||||||||||||
Unaudited | ||||||||||||||||
Three Months Ended | Year to Date | |||||||||||||||
September 27, 2024 |
September 29, 2023 |
September 27, 2024 |
September 29, 2023 |
|||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Net income | $ |
9,980 |
|
$ |
4,817 |
|
$ |
14,020 |
|
$ |
13,591 |
|
||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||||||||||
Depreciation of property and equipment |
|
1,757 |
|
|
1,345 |
|
|
4,516 |
|
|
3,743 |
|
||||
Amortization of long-lived intangibles |
|
- |
|
|
(2 |
) |
|
- |
|
|
169 |
|
||||
Accretion/Amortization of investments available for sale |
|
(124 |
) |
|
(348 |
) |
|
(410 |
) |
|
(2,172 |
) |
||||
Deferred income taxes |
|
(13 |
) |
|
(10 |
) |
|
47 |
|
|
65 |
|
||||
Change in net pension liability |
|
(16 |
) |
|
(139 |
) |
|
(162 |
) |
|
(766 |
) |
||||
Stock-based compensation expense |
|
7,160 |
|
|
8,846 |
|
|
22,541 |
|
|
23,334 |
|
||||
Change in asset retirement obligation |
|
4 |
|
|
3 |
|
|
24 |
|
|
(104 |
) |
||||
Loss on disposal of property and equipment |
|
1,642 |
|
|
17 |
|
|
1,668 |
|
|
41 |
|
||||
Provision for sales returns and bad debts |
|
868 |
|
|
921 |
|
|
1,947 |
|
|
1,925 |
|
||||
Inventory provision |
|
849 |
|
|
460 |
|
|
1,873 |
|
|
4,090 |
|
||||
Changes in working capital: | ||||||||||||||||
Accounts receivable |
|
(10,139 |
) |
|
(18,092 |
) |
|
(9,703 |
) |
|
(50,436 |
) |
||||
Inventories |
|
(1,091 |
) |
|
(5,593 |
) |
|
(5,962 |
) |
|
(9,975 |
) |
||||
Prepayments, deposits and other assets |
|
(5,152 |
) |
|
(919 |
) |
|
(12,237 |
) |
|
(3,584 |
) |
||||
Accounts payable |
|
(5,649 |
) |
|
(1,819 |
) |
|
(2,031 |
) |
|
(3,266 |
) |
||||
Other current liabilities |
|
3,740 |
|
|
4,538 |
|
|
(1,048 |
) |
|
5,970 |
|
||||
Net cash provided by (used in) operating activities |
|
3,816 |
|
|
(5,975 |
) |
|
15,083 |
|
|
(17,375 |
) |
||||
Cash flows from investing activities: | ||||||||||||||||
Acquisition of property and equipment |
|
(6,231 |
) |
|
(9,185 |
) |
|
(17,669 |
) |
|
(15,100 |
) |
||||
Purchase of investments available for sale |
|
(40,945 |
) |
|
(9,712 |
) |
|
(61,194 |
) |
|
(52,314 |
) |
||||
Proceeds from sale or maturity of investments available for sale |
|
11,935 |
|
|
50,737 |
|
|
39,141 |
|
|
119,359 |
|
||||
Net provided by (used in) investing activities |
|
(35,241 |
) |
|
31,840 |
|
|
(39,722 |
) |
|
51,945 |
|
||||
Cash flows from financing activities: | ||||||||||||||||
Repayment of finance lease obligations |
|
(42 |
) |
|
(39 |
) |
|
(124 |
) |
|
(121 |
) |
||||
Repurchase of employee common stock for taxes withheld |
|
- |
|
|
(112 |
) |
|
(1,396 |
) |
|
(2,096 |
) |
||||
Proceeds from vested restricted stock and exercise of stock options |
|
1,657 |
|
|
7,258 |
|
|
7,354 |
|
|
9,265 |
|
||||
Net cash provided by financing activities |
|
1,615 |
|
|
7,107 |
|
|
5,834 |
|
|
7,048 |
|
||||
Effect of exchange rate changes on cash and cash equivalents |
|
1,037 |
|
|
(235 |
) |
|
(230 |
) |
|
(666 |
) |
||||
Increase (decrease) in cash and cash equivalents |
|
(28,773 |
) |
|
32,737 |
|
|
(19,035 |
) |
|
40,952 |
|
||||
Cash and cash equivalents, at beginning of the period |
|
192,776 |
|
|
94,695 |
|
|
183,038 |
|
|
86,480 |
|
||||
Cash and cash equivalents, at end of the period | $ |
164,003 |
|
$ |
127,432 |
|
$ |
164,003 |
|
$ |
127,432 |
|
Reconciliation of Non-GAAP Financial Measure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income to Adjusted EBITDA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in 000's except for per share data) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2021 |
|
Q1-22 |
|
Q2-22 |
|
Q3-22 |
|
Q4-22 |
|
2022 |
|
Q1-23 |
|
Q2-23 |
|
Q3-23 |
|
Q4-23 |
|
2023 |
|
Q1-24 |
|
Q2-24 |
|
Q3-24 |
|
2024 Outlook(2) |
||||||||||||||||||||||||||||||||
Net income (loss) - (as reported) | $ |
27,511 |
|
$ |
9,602 |
|
$ |
13,038 |
|
$ |
10,262 |
|
$ |
6,763 |
|
$ |
39,665 |
|
$ |
2,710 |
|
$ |
6,064 |
|
$ |
4,817 |
|
$ |
7,756 |
|
$ |
21,347 |
|
$ |
(3,339 |
) |
$ |
7,379 |
|
$ |
9,980 |
|
$ |
3,800 |
|
|||||||||||||||
Provision (benefit) for income taxes |
|
3,793 |
|
|
1,925 |
|
|
2,431 |
|
|
2,315 |
|
|
(784 |
) |
|
5,887 |
|
|
2,009 |
|
|
2,428 |
|
|
1,929 |
|
|
5,983 |
|
|
12,349 |
|
|
1,128 |
|
|
2,955 |
|
|
3,179 |
|
|
7,600 |
|
|||||||||||||||
Other (income) expense, net |
|
2,035 |
|
|
586 |
|
|
1,551 |
|
|
1,128 |
|
|
(5,015 |
) |
|
(1,750 |
) |
|
(1,919 |
) |
|
105 |
|
|
(451 |
) |
|
(3,334 |
) |
|
(5,599 |
) |
|
(70 |
) |
|
1,564 |
|
|
(7,477 |
) |
|
(7,500 |
) |
|||||||||||||||
Depreciation |
|
3,608 |
|
|
994 |
|
|
1,030 |
|
|
1,077 |
|
|
1,380 |
|
|
4,481 |
|
|
1,113 |
|
|
1,285 |
|
|
1,345 |
|
|
1,368 |
|
|
5,111 |
|
|
1,237 |
|
|
1,522 |
|
|
1,757 |
|
|
6,000 |
|
|||||||||||||||
(Gain) loss on disposal of property plant and equipment(3) |
|
2 |
|
|
- |
|
|
- |
|
|
- |
|
|
65 |
|
|
65 |
|
|
- |
|
|
24 |
|
|
17 |
|
|
32 |
|
|
73 |
|
|
- |
|
|
26 |
|
|
1,642 |
|
|
1,700 |
|
|||||||||||||||
Amortization of intangible assets |
|
34 |
|
|
8 |
|
|
7 |
|
|
7 |
|
|
6 |
|
|
28 |
|
|
7 |
|
|
10 |
|
|
(2 |
) |
|
(2 |
) |
|
13 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|||||||||||||||
Stock-based compensation |
|
14,605 |
|
|
3,894 |
|
|
5,754 |
|
|
5,727 |
|
|
4,996 |
|
|
20,371 |
|
|
6,065 |
|
|
8,423 |
|
|
8,846 |
|
|
182 |
|
|
23,516 |
|
|
6,339 |
|
|
9,042 |
|
|
7,160 |
|
|
30,200 |
|
|||||||||||||||
Adjusted EBITDA | $ |
51,588 |
|
$ |
17,009 |
|
$ |
23,811 |
|
$ |
20,516 |
|
$ |
7,411 |
|
$ |
68,747 |
|
$ |
9,985 |
|
$ |
18,339 |
|
$ |
16,501 |
|
$ |
11,985 |
|
$ |
56,810 |
|
$ |
5,295 |
|
$ |
22,488 |
|
$ |
16,241 |
|
$ |
41,800 |
|
|||||||||||||||
Adjusted EBITDA as a % of Revenue |
|
22.4 |
% |
|
26.9 |
% |
|
29.4 |
% |
|
27.0 |
% |
|
11.6 |
% |
|
24.2 |
% |
|
13.6 |
% |
|
19.9 |
% |
|
20.6 |
% |
|
15.7 |
% |
|
17.6 |
% |
|
6.8 |
% |
|
22.7 |
% |
|
18.3 |
% |
|
12.2 |
% |
|||||||||||||||
Net income (loss) per share, diluted - (as reported) | $ |
0.56 |
|
$ |
0.19 |
|
$ |
0.26 |
|
$ |
0.21 |
|
$ |
0.14 |
|
$ |
0.80 |
|
$ |
0.05 |
|
$ |
0.12 |
|
$ |
0.10 |
|
$ |
0.16 |
|
$ |
0.43 |
|
$ |
(0.07 |
) |
$ |
0.15 |
|
$ |
0.20 |
|
$ |
0.07 |
|
|||||||||||||||
Provision (benefit) for income taxes |
|
0.08 |
|
|
0.04 |
|
|
0.05 |
|
|
0.05 |
|
|
(0.02 |
) |
|
0.12 |
|
|
0.04 |
|
|
0.05 |
|
|
0.04 |
|
|
0.12 |
|
|
0.25 |
|
|
0.02 |
|
|
0.06 |
|
|
0.06 |
|
|
0.15 |
|
|||||||||||||||
Other (income) expense, net |
|
0.04 |
|
|
0.01 |
|
|
0.03 |
|
|
0.02 |
|
|
(0.10 |
) |
|
(0.04 |
) |
|
(0.04 |
) |
|
- |
|
|
(0.01 |
) |
|
(0.07 |
) |
|
(0.11 |
) |
|
- |
|
|
0.03 |
|
|
(0.15 |
) |
|
(0.14 |
) |
|||||||||||||||
Depreciation |
|
0.07 |
|
|
0.02 |
|
|
0.02 |
|
|
0.02 |
|
|
0.03 |
|
|
0.09 |
|
|
0.02 |
|
|
0.03 |
|
|
0.03 |
|
|
0.03 |
|
|
0.10 |
|
|
0.03 |
|
|
0.03 |
|
|
0.04 |
|
|
0.12 |
|
|||||||||||||||
(Gain) loss on disposal of property plant and equipment |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
0.03 |
|
|
0.03 |
|
|||||||||||||||
Amortization of intangible assets |
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|||||||||||||||
Stock-based compensation |
|
0.30 |
|
|
0.08 |
|
|
0.12 |
|
|
0.12 |
|
|
0.10 |
|
|
0.41 |
|
|
0.12 |
|
|
0.17 |
|
|
0.18 |
|
|
- |
|
|
0.48 |
|
|
0.13 |
|
|
0.18 |
|
|
0.14 |
|
|
0.58 |
|
|||||||||||||||
Adjusted EBITDA per share, diluted(1) | $ |
1.04 |
|
$ |
0.35 |
|
$ |
0.48 |
|
$ |
0.41 |
|
$ |
0.15 |
|
$ |
1.39 |
|
$ |
0.20 |
|
$ |
0.37 |
|
$ |
0.33 |
|
$ |
0.24 |
|
$ |
1.15 |
|
$ |
0.11 |
|
$ |
0.45 |
|
$ |
0.33 |
|
$ |
0.80 |
|
|||||||||||||||
Weighted average shares outstanding - Diluted |
|
49,456 |
|
|
49,288 |
|
|
49,223 |
|
|
49,549 |
|
|
49,389 |
|
|
49,380 |
|
|
49,500 |
|
|
49,516 |
|
|
49,370 |
|
|
49,242 |
|
|
49,427 |
|
|
48,907 |
|
|
49,811 |
|
|
49,731 |
|
|
52,000 |
|
|||||||||||||||
(1) Adjusted EBITDA per diluted share may not add due to rounding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2) 2024 Adjusted EBITDA Outlook line items are all approximations and assumes breakeven Net Income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(3) The Q3-2024 non cash write-off of |
ICL Sales by Geography | ||||||||||||||||||||||||||||||||||||
(in 000's) | ||||||||||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||||||||
Fiscal Year | Three Months Ended | |||||||||||||||||||||||||||||||||||
ICL Sales by Region(5) | 2021 |
2022 |
2023 |
June 30, 2023 |
September 29, 2023 |
December 29, 2023 |
March 29, 2024 |
June 28, 2024 |
September 27, 2024 |
|||||||||||||||||||||||||||
$ |
14,054 |
|
$ |
20,114 |
|
$ |
22,233 |
|
$ |
5,954 |
|
$ |
5,449 |
|
$ |
5,264 |
|
$ |
6,260 |
|
$ |
6,794 |
|
$ |
6,187 |
|
||||||||||
EMEA(2) |
|
37,343 |
|
|
36,715 |
|
|
39,318 |
|
|
9,782 |
|
|
9,253 |
|
|
10,103 |
|
|
11,299 |
|
|
10,727 |
|
|
10,333 |
|
|||||||||
APAC(3) |
|
161,508 |
|
|
212,883 |
|
|
257,876 |
|
|
77,376 |
|
|
66,367 |
|
|
59,254 |
|
|
59,592 |
|
|
81,844 |
|
|
72,581 |
|
|||||||||
Global ICL Sales | $ |
212,905 |
|
$ |
269,712 |
|
$ |
319,427 |
|
$ |
93,112 |
|
$ |
81,069 |
|
$ |
74,621 |
|
$ |
77,151 |
|
$ |
99,365 |
|
$ |
89,101 |
|
|||||||||
Global ICL Sales Growth |
|
51 |
% |
|
27 |
% |
|
18 |
% |
|
19 |
% |
|
13 |
% |
|
22 |
% |
|
9 |
% |
|
7 |
% |
|
10 |
% |
|||||||||
Americas ICL Sales Growth |
|
59 |
% |
|
43 |
% |
|
11 |
% |
|
12 |
% |
|
5 |
% |
|
(8 |
)% |
|
12 |
% |
|
14 |
% |
|
14 |
% |
|||||||||
EMEA ICL Sales Growth |
|
45 |
% |
|
(2 |
)% |
|
7 |
% |
|
(11 |
)% |
|
14 |
% |
|
18 |
% |
|
11 |
% |
|
10 |
% |
|
12 |
% |
|||||||||
APAC ICL Sales Growth |
|
51 |
% |
|
32 |
% |
|
21 |
% |
|
26 |
% |
|
13 |
% |
|
26 |
% |
|
9 |
% |
|
6 |
% |
|
9 |
% |
|||||||||
Global ICL Unit Growth |
|
48 |
% |
|
33 |
% |
|
19 |
% |
|
21 |
% |
|
14 |
% |
|
19 |
% |
|
2 |
% |
|
3 |
% |
|
6 |
% |
|||||||||
Fiscal Year | Three Months Ended | |||||||||||||||||||||||||||||||||||
ICL Sales by Country(4)(5) | 2021 |
2022 |
2023 |
June 30, 2023 |
September 29, 2023 |
December 29, 2023 |
March 29, 2024 |
June 28, 2024 |
September 27, 2024 |
|||||||||||||||||||||||||||
$ |
107,130 |
|
$ |
147,967 |
|
$ |
185,404 |
|
$ |
61,288 |
|
$ |
48,262 |
|
$ |
40,813 |
|
$ |
38,460 |
|
$ |
63,345 |
|
$ |
51,719 |
|
||||||||||
Growth |
|
50 |
% |
|
38 |
% |
|
25 |
% |
|
33 |
% |
|
14 |
% |
|
30 |
% |
|
10 |
% |
|
3 |
% |
|
7 |
% |
|||||||||
$ |
28,688 |
|
$ |
32,623 |
|
$ |
36,352 |
|
$ |
8,563 |
|
$ |
9,091 |
|
$ |
9,495 |
|
$ |
10,227 |
|
$ |
9,735 |
|
$ |
10,490 |
|
||||||||||
Growth |
|
56 |
% |
|
14 |
% |
|
11 |
% |
|
13 |
% |
|
12 |
% |
|
16 |
% |
|
11 |
% |
|
14 |
% |
|
15 |
% |
|||||||||
$ |
15,173 |
|
$ |
17,940 |
|
$ |
19,853 |
|
$ |
3,316 |
|
$ |
4,886 |
|
$ |
4,996 |
|
$ |
6,725 |
|
$ |
3,973 |
|
$ |
5,434 |
|
||||||||||
Growth |
|
36 |
% |
|
18 |
% |
|
11 |
% |
|
(15 |
)% |
|
1 |
% |
|
39 |
% |
|
1 |
% |
|
20 |
% |
|
11 |
% |
|||||||||
$ |
9,478 |
|
$ |
15,070 |
|
$ |
17,168 |
|
$ |
4,446 |
|
$ |
4,162 |
|
$ |
4,164 |
|
$ |
5,039 |
|
$ |
5,541 |
|
$ |
4,823 |
|
||||||||||
Growth |
|
58 |
% |
|
59 |
% |
|
14 |
% |
|
10 |
% |
|
6 |
% |
|
(8 |
)% |
|
15 |
% |
|
25 |
% |
|
16 |
% |
|||||||||
Notes: | ||||||||||||||||||||||||||||||||||||
(1) |
||||||||||||||||||||||||||||||||||||
(2) EMEA includes |
||||||||||||||||||||||||||||||||||||
(3) APAC includes |
||||||||||||||||||||||||||||||||||||
(4) ICL Sales by country includes countries representing more than |
||||||||||||||||||||||||||||||||||||
(5) ICL sales do not include IOL, injector or other sales |
Reconciliation of Non-GAAP Financial Measure | ||||||||||||||||||||||||||||||
Constant Currency Sales | ||||||||||||||||||||||||||||||
(in 000's) | ||||||||||||||||||||||||||||||
Unaudited | ||||||||||||||||||||||||||||||
Three Months Ended | As Reported | Constant Currency | ||||||||||||||||||||||||||||
Sales | September 27, 2024 |
Effect of Currency |
Constant Currency |
September 29, 2023 |
$ Change |
% Change |
$ Change |
% Change |
||||||||||||||||||||||
ICL | $ |
89,101 |
|
$ |
300 |
|
$ |
89,401 |
|
$ |
81,069 |
|
$ |
8,032 |
|
9.9 |
% |
$ |
8,332 |
|
10.3 |
% |
||||||||
Cataract IOL |
|
- |
|
|
- |
|
|
- |
|
|
(221 |
) |
|
221 |
|
(100.0 |
)% |
|
221 |
|
(100.0 |
)% |
||||||||
Other |
|
(511 |
) |
|
(2 |
) |
|
(513 |
) |
|
(540 |
) |
|
29 |
|
(5.4 |
)% |
|
27 |
|
(5.0 |
)% |
||||||||
Total Sales | $ |
88,590 |
|
$ |
298 |
|
$ |
88,888 |
|
$ |
80,308 |
|
$ |
8,282 |
|
10.3 |
% |
$ |
8,580 |
|
10.7 |
% |
||||||||
Year to Date | As Reported | Constant Currency | ||||||||||||||||||||||||||||
Sales | September 27, 2024 |
Effect of Currency |
Constant Currency |
September 29, 2023 |
$ Change |
% Change |
$ Change |
% Change |
||||||||||||||||||||||
ICL | $ |
265,617 |
|
$ |
2,515 |
|
$ |
268,132 |
|
$ |
244,806 |
|
$ |
20,811 |
|
8.5 |
% |
$ |
23,326 |
|
9.5 |
% |
||||||||
Cataract IOL |
|
- |
|
|
- |
|
|
- |
|
|
1,295 |
|
|
(1,295 |
) |
(100.0 |
)% |
|
(1,295 |
) |
(100.0 |
)% |
||||||||
Other |
|
(666 |
) |
|
111 |
|
|
(555 |
) |
|
41 |
|
|
(707 |
) |
(1724.4 |
)% |
|
(596 |
) |
(1453.7 |
)% |
||||||||
Total Sales | $ |
264,951 |
|
$ |
2,626 |
|
$ |
267,577 |
|
$ |
246,142 |
|
$ |
18,809 |
|
7.6 |
% |
$ |
21,435 |
|
8.7 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030604379/en/
Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
626-303-7902, Ext. 3023
bmoore@staar.com
Investors –
Niko Liu, CFA
Director, Investor Relations and Corporate Development –
+852-6092-5076
nliu@staar.com
Source: STAAR Surgical Company
FAQ
What was STAAR Surgical's (STAA) revenue growth in Q3 2024?
How did STAAR Surgical's (STAA) regional sales perform in Q3 2024?
What was STAAR Surgical's (STAA) net income for Q3 2024?